Synovus Financial Corp Has $714,000 Holdings in Humana Inc. (NYSE:HUM)

Synovus Financial Corp raised its position in Humana Inc. (NYSE:HUM) by 4.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,254 shares of the insurance provider’s stock after buying an additional 89 shares during the period. Synovus Financial Corp’s holdings in Humana were worth $714,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp boosted its position in Humana by 1.0% in the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after buying an additional 53,272 shares in the last quarter. FMR LLC boosted its position in Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after buying an additional 643,291 shares in the last quarter. Pzena Investment Management LLC boosted its position in Humana by 8.1% in the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after buying an additional 187,903 shares in the last quarter. Davis Selected Advisers boosted its position in Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after buying an additional 321,233 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after buying an additional 774,085 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 10.2 %

Shares of NYSE:HUM opened at $233.89 on Wednesday. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $475.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market capitalization of $28.16 billion, a PE ratio of 20.72, a PEG ratio of 2.15 and a beta of 0.53. The company has a 50 day moving average price of $274.43 and a two-hundred day moving average price of $322.89.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Analysts forecast that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.51%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is 31.36%.

Wall Street Analyst Weigh In

HUM has been the topic of a number of research reports. Leerink Partners lowered shares of Humana from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Truist Financial reduced their target price on shares of Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a research report on Friday, October 11th. Barclays upped their target price on shares of Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. KeyCorp initiated coverage on shares of Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, Oppenheimer reduced their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus target price of $300.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.